NYKODE THERAPEUTICS ASA (NYKD.OL) Stock Fundamental Analysis
Europe - Euronext Oslo - OSL:NYKD - NO0010714785 - Common Stock
2.552 NOK
-0.05 (-2.07%)
Taking everything into account, NYKD scores 3 out of 10 in our fundamental rating. NYKD was compared to 83 industry peers in the Biotechnology industry. While NYKD seems to be doing ok healthwise, there are quite some concerns on its profitability. NYKD is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
NYKD had negative earnings in the past year.
In the past year NYKD has reported a negative cash flow from operations.
In the past 5 years NYKD reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: NYKD reported negative operating cash flow in multiple years.
1.2 Ratios
NYKD has a better Return On Assets (-10.38%) than 61.45% of its industry peers.
NYKD has a Return On Equity of -11.11%. This is in the better half of the industry: NYKD outperforms 68.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.38% | ||
| ROE | -11.11% | ||
| ROIC | N/A |
ROA(3y)-20.54%
ROA(5y)-0.01%
ROE(3y)-25.46%
ROE(5y)0.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NYKD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
NYKD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NYKD has about the same amount of shares outstanding.
Compared to 5 years ago, NYKD has more shares outstanding
Compared to 1 year ago, NYKD has an improved debt to assets ratio.
2.2 Solvency
NYKD has an Altman-Z score of 7.81. This indicates that NYKD is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of NYKD (7.81) is better than 85.54% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that NYKD is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.02, NYKD is doing good in the industry, outperforming 74.70% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.81 |
ROIC/WACCN/A
WACC8.54%
2.3 Liquidity
NYKD has a Current Ratio of 17.14. This indicates that NYKD is financially healthy and has no problem in meeting its short term obligations.
NYKD's Current ratio of 17.14 is amongst the best of the industry. NYKD outperforms 97.59% of its industry peers.
NYKD has a Quick Ratio of 17.14. This indicates that NYKD is financially healthy and has no problem in meeting its short term obligations.
NYKD has a better Quick ratio (17.14) than 97.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 17.14 | ||
| Quick Ratio | 17.14 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 90.47% over the past year.
NYKD shows a strong growth in Revenue. In the last year, the Revenue has grown by 72.62%.
NYKD shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -36.54% yearly.
EPS 1Y (TTM)90.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)72.62%
Revenue growth 3Y-36.54%
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
Based on estimates for the next years, NYKD will show a very negative growth in Earnings Per Share. The EPS will decrease by -66.63% on average per year.
Based on estimates for the next years, NYKD will show a very strong growth in Revenue. The Revenue will grow by 184.95% on average per year.
EPS Next Y74.49%
EPS Next 2Y14.88%
EPS Next 3Y16.34%
EPS Next 5Y-66.63%
Revenue Next Year-72.85%
Revenue Next 2Y-41.42%
Revenue Next 3Y52.25%
Revenue Next 5Y184.95%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NYKD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NYKD. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as NYKD's earnings are expected to grow with 16.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.88%
EPS Next 3Y16.34%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 43.10%, NYKD is a good candidate for dividend investing.
NYKD's Dividend Yield is rather good when compared to the industry average which is at 8.14. NYKD pays more dividend than 100.00% of the companies in the same industry.
NYKD's Dividend Yield is rather good when compared to the S&P500 average which is at 2.31.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 43.1% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y14.88%
EPS Next 3Y16.34%
OSL:NYKD (12/9/2025, 7:00:00 PM)
2.552
-0.05 (-2.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners15.07%
Inst Owner ChangeN/A
Ins Owners0.96%
Ins Owner ChangeN/A
Market Cap833.36M
Revenue(TTM)6.77M
Net Income(TTM)-11.00M
Analysts42.22
Price Target5.46 (113.95%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 43.1% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.88%
PT rev (3m)3.88%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-50%
EPS NY rev (3m)57.14%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)100%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 12.17 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.83 | ||
| P/tB | 0.83 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.12
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)-1.09
FCFYN/A
OCF(TTM)-1.08
OCFYN/A
SpS0.21
BVpS3.08
TBVpS3.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.38% | ||
| ROE | -11.11% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-20.54%
ROA(5y)-0.01%
ROE(3y)-25.46%
ROE(5y)0.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 4.31% | ||
| Cap/Sales | 1.33% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 17.14 | ||
| Quick Ratio | 17.14 | ||
| Altman-Z | 7.81 |
F-Score5
WACC8.54%
ROIC/WACCN/A
Cap/Depr(3y)80.07%
Cap/Depr(5y)78.31%
Cap/Sales(3y)17.62%
Cap/Sales(5y)11.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y74.49%
EPS Next 2Y14.88%
EPS Next 3Y16.34%
EPS Next 5Y-66.63%
Revenue 1Y (TTM)72.62%
Revenue growth 3Y-36.54%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-72.85%
Revenue Next 2Y-41.42%
Revenue Next 3Y52.25%
Revenue Next 5Y184.95%
EBIT growth 1Y55.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year47.75%
EBIT Next 3Y17.92%
EBIT Next 5Y-60.17%
FCF growth 1Y44.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.38%
OCF growth 3YN/A
OCF growth 5YN/A
NYKODE THERAPEUTICS ASA / NYKD.OL FAQ
What is the ChartMill fundamental rating of NYKODE THERAPEUTICS ASA (NYKD.OL) stock?
ChartMill assigns a fundamental rating of 3 / 10 to NYKD.OL.
What is the valuation status for NYKD stock?
ChartMill assigns a valuation rating of 0 / 10 to NYKODE THERAPEUTICS ASA (NYKD.OL). This can be considered as Overvalued.
What is the profitability of NYKD stock?
NYKODE THERAPEUTICS ASA (NYKD.OL) has a profitability rating of 1 / 10.
What is the financial health of NYKODE THERAPEUTICS ASA (NYKD.OL) stock?
The financial health rating of NYKODE THERAPEUTICS ASA (NYKD.OL) is 6 / 10.